亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

隨州市紅旗化工有限公司  

醫藥原料醫藥中間體原料藥

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 吲達帕胺 CAS號: 26807-65-8
吲達帕胺 CAS號: 26807-65-8
單價 面議對比
詢價 暫無
發貨 湖北隨州市付款后3天內
型號 26807-65-8
過期 長期有效
更新 2020-06-18 10:08
 
詳細信息
 吲達帕胺
CAS號: 26807-65-8
中文同義詞: N-(2-甲基-2,3-二氫-1H-吲哚基)-3-氨磺酰基-4-氯-苯甲酰胺;吲達帕胺;吲滿胺;吲滿速尿;茚磺苯酰胺;吲噠帕胺;吲達帕安
英文名稱: Indapamide
英文同義詞: N-(4-CHLORO-3-SULFAMOYLBENZAMIDO)-2-METHYLINDOLINE;N-[4-CHLORO-3-SULFAMOYL-BENZAMIDOL]-2-METHYLINDOLINE;INDAPAMIDE;1-(4-chloro-3-sulfamoylbenzamido)-2-methylindoline;3-(aminosulfonyl)-4-chloro-n-(2,3-dihydro-2-methyl-1h-indol-1-yl)-benzamid;3-(aminosulfonyl)-4-chloro-n-(2,3-dihydro-2-methyl-1h-indol-1-yl)benzamide;4-chloro-n-(2-methyl-1-indolinyl)-3-sulfamoyl-benzamid;4-chloro-n-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide
分子式: C16H16ClN3O3S
分子量: 365.83
EINECS號: 248-012-7
熔點  160-162°C
標準:國藥標準
含量:995-101%
性狀:白色針狀結晶或結晶性粉末無臭無味
用途:磺胺類利尿藥,具有利尿和鈣拮抗作用,是一種強效、長效的降壓藥。臨床上還用于充血性心力衰竭時水鈉潴留的治療。
包裝;25kg/桶
©2025 隨州市紅旗化工有限公司 版權所有   技術支持:化工網   訪問量:31441  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |